InDevR raises $9 Million in Series B Financing and Partners with bioMérieux
New partnerships will drive the commercial expansion of InDevR’s game-changing solutions for vaccines and biotherapeutics
Boulder, CO — News Direct– InDevR
InDevR, Inc., which provides the best-in-class analytical technology for vaccines, and biotherapeutics, has announced it has raised $9M in Series B financing. Adjuvant Capital has invested $4 million, and bioMérieux – a worldwide leader in In vitro diagnostics and microbiological quality control solutions for the food and pharmaceutical industries – $5 million. Together, these investments will support InDevR’s commercial expansion and ongoing development of new reagent kits for its VaxArray® platform. bioMérieux will also become the exclusive distributor of the VaxArray portfolio in Europe, and Michael Reynier, Senior Vice President of Pharma Quality Control at bioMérieux, will join the company’s board of directors.
VaxArray is based upon a versatile, multiplexed technology that uses microarrays to identify and quantify specific antigens, antibodies, and nucleic acids. This includes mRNA. This technology complements bioMérieux’s expertise in applying immunoassays to vaccine production, as Michael explained: “We quickly recognized the high quality of InDevR’s products and team, and realized that we share a common vision and mindset. This partnership reflects our desire to expand our offerings with high value-added solutions for pharmaceutical companies.”
Glenn Rockman, Managing Partner at Adjuvant Capital, commented: “InDevR has already successfully developed critical quality attribute (CQA)/QC tools for pneumococcus, polio, measles and rubella vaccines, as well as for mRNA vaccines. We have been impressed with InDevR’s efficiency and dedication, and we are delighted to continue supporting the company alongside the experienced team at bioMérieux.”
Kathy Rowlen, CEO at InDevR, said: “I am grateful for the opportunity to continue our successful partnership with Adjuvant Capital, and to work with the talented team at bioMérieux. The expertise at bioMérieux, combined with our innovation engine, will ensure that our CQA/QC tools are backed by a trusted partner who understands the needs of the highly regulated pharma industry.”
VaxArray is also a great solution for mRNA CQA/QC testing. It provides high specificity, sensitivity and eliminates the need to extract mRNA from nanoparticles.1 Kathy added: “We are on a mission to revolutionize CQA/QC testing for vaccines and therapeutics. VaxArray allows us to coordinate the rapid advancement in mRNA vaccines, cell and gene therapies, with more efficient and cost-effective analytical instruments. And the partnership with bioMérieux accelerates our efforts to achieve this goal.”
About InDevR – InDevR is a Boulder-based company that offers high-quality analytical test kits to perform CQA and QC testing in vaccines and other biotherapeutics.
Refer to
Gao RY, Riley CM, Toth E, et. al.. Rapid Identification and Quantity CQA Test For Multivalent mRNA Drug Product Formulations Vaccines. 2022;10(10):1704. doi:10.3390/vaccines10101704
Contact Details
kdm communications limited
Annette Barnard
+44 1480 405333
Source version available at newsdirect.com https://newsdirect.com/news/indevr-raises-9-million-in-series-b-financing-and-partners-with-biomerieux-666283641